Follow-up clinical characteristics of evolution after RYBG and AGB
| Gastric bypass (n=41) | AGB (n=10) | |||||||
| T0 | T1 | T3 | T12 | T0 | T1 | T3 | T12 | |
| Anthropometry | ||||||||
| Weight (kg) | 123±16.4 | 113±15 (*#) | 103±14.9 (*#) | 85.3±17 (*#) | 113±7.12 | 108±9 (*) | 101±8.93 (*#) | 93.7±5.97 (*#) |
| BMI (kg/m2) | 46.3±6.22 | 42.4±6.09 (*#) | 39.3±6.21 (*#) | 32.2±6.95 (*#) | 43±2.22 | 40.8±3.26 (*) | 38.2±3.45 (*#) | 35.7±2.34 (*#) |
| Fat-free mass (kg) | 58.2±6.88 | 53.2±6.6 (*#) | 51.4±5.1 (*#) | 48.6±5.3 (*#) | 54.9±4.7 | 52.8±4.5 | 51.2±3.1 (*#) | 49.5±3.4 (*#) |
| Fat mass (kg) | 60.9±11 | 56.5±9.6 (*#) | 49.7±10 (*#) | 34.7±11.5 (*#+) | 55.7±6.4 | 51.8±6.9 (*) | 47.4±7. (*#) | 42.4±5.1 (*#+) |
| Trunk-fat mass (kg) | 30.4±5.59 | 27.6±5.3 (*#) | 23.9±4.4 (*#) | 15.6±5.9 (*#) | 26.7±3.4 | 24.3±3.6 (*) | 22±4.2 (*#) | 18.8±3.4 (*#) |
| Leptin (ng/mL) | 81.4±28.2 | 51.9±28.2 (*#) | 39.8±25.5 (*#) | 27.6±27.2 (*#) | 74.1±26.5 | 48±20 (*) | 31.7±9.43 (*#) | 40.3±15.7 (*#) |
| Obesity-related diseases | ||||||||
| Hypertension (%) | 57.1 | 50 | 57.1 | 21.4 | 20 | 40 | 40 | 30 |
| Dyslipidaemia (%) | 100 | 92.9 (*#) | 85.7 (*#) | 57.1 | 80 | 80 (*) | 80 | 30 |
| Diabetes (%) | 35.7 (+) | 7.14 | 7.14 | 7.14 | 0 | 0 | 0 | 0 |
| Glucose intolerance (%) | 50 | 42.9 | 35.7 | 21.4 | 40 | 10 | 20 | 0 (*) |
| Biology | ||||||||
| Total cholesterol (mmol/L) | 5.24±1.33 | 4.45±0.97 (*#) | 4.48±0.77 (*#) | 4.38±0.65 (*#) | 4.57±0.68 | 4.6±0.98 | 4.48±0.85 | 4.73±0.69 |
| HDL-cholesterol (mmol/L) | 1.15±0.46 | 1.01±0.35 (*) | 1.08±0.32 | 1.45±0.35 (*#) | 1.12±0.29 | 1.1±0.24 | 1.1±0.19 | 1.38±0.3 (*#) |
| LDL-cholesterol (mmol/L) | 3.38±1.23 | 2.79±0.95 | 2.85±0.76 | 2.5±0.63 (*#) | 2.98±0.52 | 3.07±0.82 | 2.97±0.7 | 3±0.64 |
| Triglycerides (mmol/L) | 1.58±0.58 (+) | 1.43±0.4 (+§) | 1.23±0.32 (*#+) | 0.946±0.34 (*#) | 1.01±0.43 (+) | 0.939±0.42 (+§) | 0.887±0.33 (+) | 0.767±0.28 (*#) |
| Fasting glucose (mmol/L) | 5.98±1.83 | 5.33±1.18 (*#) | 4.89±0.79 (*#) | 4.64±0.94 (*#) | 5.34±0.6 | 4.9±0.2 (*) | 4.93±0.52 | 4.69±0.37 (*#) |
| Insulin (mmol/L) | 22±9.34 | 12.2±5.75 (*#) | 12.5±5.53 (*#) | 6.95±3.4 (*#+) | 27.8±27 | 26.5±32.6 | 13.2±6.35 (*#) | 11.8±3.02 (*#+) |
| HbA1c (%) | 6.21±0.88 (+) | 5.89±0.71 (*#) | 5.68±0.55 (*#) | 5.72±0.61 (*#+) | 5.61±0.41 (+) | 5.4±0.4 | 5.31±0.44 (*#) | 5.24±0.37 (*#+) |
| HOMA-IR | 3.28±1.27 | 1.82±0.79 (*#) | 1.79±0.77 (*#) | 0.707±0.21 (*#) | 3.91±3.54 | 3.53±3.85 | 1.91±0.85 (*#) | 0.696±0.06 (*#) |
| Adiponectin (µg/mL) | 3.89±1.79 | 4.89±1.72 (*#) | 5.19±3.05 (*#) | 6.91±2.4 (*#) | 4.14±1.34 | 4.01±1.54 | 4.44±1.38 | 5.17±1.73 (*#) |
| ALAT (IU/L) | 31.7±23.4 | 56.1±26.7 (*#+§) | 47.7±33.9 (*#+§) | 24.5±8.45 (+) | 27.7±22.7 | 19.2±9.79 (+§) | 17.1±6.82 (+§) | 15.9±4.86 (*#+) |
| ASAT (IU/L) | 26.4±7.98 | 37.9±9.76 (*#+§) | 41.4±27.7 (*#+§) | 25.9±4.37 | 26.3±7.67 | 22±4.81 (+§) | 20.5±2.92 (*#+§) | 23.1±4.63 |
| GGT (IU/L) | 46.6±28.3 | 52.3±32.8 (+§) | 31.7±23.6 (*#) | 25.1±14.9 (*#) | 30.1±12.8 | 21.6±7.39 (+§) | 19.8±7.33 (*#) | 21.1±8.02 (*#) |
| IL6 (pg/mL) | 4.44±1.85 | 3.75±1.08 | 4.12±1.52 | 2.61±1.43 (*#) | 3.78±2.86 | 6.36±4 | 3.25±1.54 | 29.6±75 |
| CRP (mg/L) | 7.51±3.27 | 3.44±2.57 (*#) | 4.79±3.83 | 1.33±1.78 (*#+) | 7.35±4.57 | 4.05±2.65 | 3.2±2.23 (*#) | 3.33±2.34 (*#+) |
Significant differences between baseline and follow-up time points for each surgery group (*) and when FDR is significant (#). (+) Significant differences between RYGB and AGB at the same time points and (§) when FDR is significant.
AGB, adjustable gastric banding; ALT, alanine aminotransferase; AST, aspartate transaminase; BMI, body mass index; CRP, C reactive protein; GGT, gammaglutamyl- transférases; HbA1c, haemoglobin A1c; HDL, high density lipoprotein; HOMA-IR, homeostatic model assessment insulin resistance; IL, interleukin-6; LDL, low density lipoprotein; RYBG, Roux-en-Y-gastric bypass; T0, baseline; T1, 1 month; T3, 3 months; T12, 12 months.